or Try an Advanced Search...

    Cd20 Stocks List

    Symbol Grade Name % Change
    TGTX A TG Therapeutics, Inc. 7.34
    GMAB F Genmab A/S 1.08
    BIIB F Biogen Idec Inc. -0.12
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Long-Term Care Facilities
    Related Stock Lists: Lymphoma Monoclonal Antibodies Monoclonal Antibody Antibody Drug Conjugate Biotechnology Camidanlumab Tesirine Cancer Chronic Lymphocytic Leukemia Immunology Lymphocytic Leukemia Medicine Multiple Sclerosis Treatment Of Cancer Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Alzheimer's Disease Amyloid Amyloidosis Antibodies

    Related ETFs - A few ETFs which own one or more of the above listed Cd20 stocks.

    Symbol Grade Name Weight
    PBE C PowerShares Dynamic Biotech & Genome 7.66
    FBT A First Trust Amex Biotech Index Fund 6.64
    BIS C ProShares UltraShort Nasdaq Biotechnology 6.12
    BBH D Market Vectors Biotech ETF 4.15
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 3.91
    View all Cd20 ETFs...
    Compare ETFs
    Compare BIS to BBH Compare PBE to BIS Compare PBE to FTXH

        Cd20 Stocks Recent News

        Date Stock Title
        Nov 1 BIIB Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
        Nov 1 TGTX TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
        Nov 1 BIIB Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        Oct 31 BIIB Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
        Oct 31 TGTX Is TG Therapeutics, Inc. (TGTX) Set to Explode in 2025?
        Oct 31 BIIB Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
        Oct 31 BIIB Biogen slips as Morgan Stanley downgrades on Leqembi launch
        Oct 31 BIIB Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
        Oct 30 BIIB Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
        Oct 30 BIIB Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
        Oct 30 BIIB Biogen and Neomorph enter molecular glue degrader deal
        Oct 30 BIIB Biogen (BIIB) Q3 2024 Earnings Call Transcript
        Oct 30 BIIB Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
        Oct 30 BIIB Biogen raises 2024 EPS guidance with strong Q3 results
        Oct 30 BIIB Biogen Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 30 BIIB Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.
        Oct 30 BIIB SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
        Oct 30 BIIB Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
        Oct 30 BIIB Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
        Oct 30 BIIB Biogen, Sage admit a defeat in major depression
        Related Industries: Biotechnology Drug Manufacturers - Major Long-Term Care Facilities
        Related Stock Lists: Lymphoma Monoclonal Antibodies Monoclonal Antibody Antibody Drug Conjugate Biotechnology Camidanlumab Tesirine Cancer Chronic Lymphocytic Leukemia Immunology Lymphocytic Leukemia Medicine Multiple Sclerosis Treatment Of Cancer Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Alzheimer's Disease Amyloid Amyloidosis Antibodies
        Cd20

        Browse All Tags